CHICAGO — Multiple intravitreal administrations of KSI-301, a novel anti-VEGF antibody biopolymer conjugate, improved best corrected visual acuity and retinal anatomy in patients with wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion, a speaker said here.
“Antibody biopolymer conjugates, or ABCs, are a new scientific approach and design platform for intravitreal drugs. KSI-301 from Kodiak Sciences has achieved its early development goals of demonstrating strong efficacy and excellent safety in major retinal vascular diseases,” Pravin U.
Uncategorized